Neurotech reports positive results form Phase II dry AMD trial
Neurotech Pharmaceuticals, a biotechnology company, has announced that the company’s lead product candidate, NT-501, substantially slowed the loss of vision in a Phase II clinical trial in subjects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.